The American health system is poised to incur $55 billion in excess costs from pharmaceutical companies’ strategies to delay competition on three drugs
The American health system is poised to incur $55 billion in excess costs from pharmaceutical companies’ strategies to delay competition on three drugs
Learn more about how you can help build a more equitable system for all